K monotherapy or in combination with chemotherapy or other targeted agents Can additionally these new therapies Tzlichen clinical benefit for patients with aggressive NHL offer of B cells E is for continued progress in the search for individualized Zibotentan therapies. As individualized therapy is dependent on the identification of markers predictive of future clinical trials Nts should the identification of molecular markers in their study design intelligently. As the search for individualized treatment affect the development of drugs and improve the design of clinical trials remains to be seen. Breast cancer molecular subtypes and several diff erent diff erent biological processes, and therefore diff erent molecular markers with prognosis and chemotherapy sensitivity of disease associated with different sub-groups composed. A variety of biological processes, including normal cell cycle regulation, DNA replication, mitotic spindle checkpoint and p53 function are strongly prognostic in cancer ER, but not ER among cancers. Interestingly, the number of biological processes, and therefore the genes that are associated with sensitivity prognosis or treatment are clearly gr He and consistent in cancer tumors since ER ER.
This implies there it easier to detect and pr predictive prognostic factors for cancer is ER ER. In cancer, ER, the Ndiger best, but still modestly accurate indicator of prognosis, the presence of immune cells infi ltration. Signatures of immune cells are also associated with a better prognosis strong proliferative cancers ER, but not ER cancers with low proliferation. It is also increasingly clear that the same PD173074 molecular marker may be several diff erent parameters results connected in different ways and often contradictory. For example, a high Ki67 Pr Predictor of poor prognosis in the absence of systemic therapy of cancer ER, but at the same time it is also pr Diktiven gr Erer sensitivity to chemotherapy. Unlike anything similar bidirectional associations with treatment response and prognosis, there are many other markers including normal histological grade, expression of tau proteins And almost all prognostic gene signatures.
It is important to know these complex multi-directional interactions between molecular markers and different clinical parameters that vary from one subtype of breast cancer subtype. Ignoring these potential markers interactions between disease subset of results k Can cause contradictory and confusing results between studies and may also on the discovery of biomarkers that lead less clinically useful. Triple negative breast cancer go Are among the clinically difficult because of their poor prognosis and few Behandlungsm Opportunities. Also due to our genomic profiling studies, breast cancer is now recognized as a disease of several together. One of these diseases, the basal subtype, such as breast cancer, which is now known to be a single unit with a significant disease etiology And biology repr sentieren. Over the years were BLBC better known as TNBC known because most of these tumors are not the expression of ER, PR and HER2 are not all TNBC BLBC, and all are BLBC TNBC.